TY - JOUR
T1 - Transcatheter Edge-to-Edge Repair in Patients With Anatomically Complex Degenerative Mitral Regurgitation
AU - the PASCAL IID Registry Investigators
AU - Hausleiter, Jörg
AU - Lim, D. Scott
AU - Gillam, Linda D.
AU - Zahr, Firas
AU - Chadderdon, Scott
AU - Rassi, Andrew N.
AU - Makkar, Raj
AU - Goldman, Scott
AU - Rudolph, Volker
AU - Hermiller, James
AU - Kipperman, Robert M.
AU - Dhoble, Abhijeet
AU - Smalling, Richard
AU - Latib, Azeem
AU - Kodali, Susheel K.
AU - Lazkani, Mohamad
AU - Choo, Joseph
AU - Lurz, Philipp
AU - O'Neill, William W.
AU - Laham, Roger
AU - Rodés-Cabau, Josep
AU - Kar, Saibal
AU - Schofer, Niklas
AU - Whisenant, Brian
AU - Inglessis-Azuaje, Ignacio
AU - Baldus, Stephan
AU - Kapadia, Samir
AU - Koulogiannis, Konstantinos
AU - Marcoff, Leo
AU - Smith, Robert L.
N1 - Publisher Copyright:
© 2023 American College of Cardiology Foundation
PY - 2023/2/7
Y1 - 2023/2/7
N2 - Background: Mitral valve transcatheter edge-to-edge repair is safe and effective in treating degenerative mitral regurgitation (DMR) patients at prohibitive surgical risk, but outcomes in complex mitral valve anatomy patients vary. Objectives: The PASCAL IID registry assessed safety, echocardiographic, and clinical outcomes with the PASCAL system in prohibitive risk patients with significant symptomatic DMR and complex mitral valve anatomy. Methods: Patients in the prospective, multicenter, single-arm registry had 3+ or 4+ DMR, were at prohibitive surgical risk, presented with complex anatomic features based on the MitraClip instructions for use, and were deemed suitable for the PASCAL system by a central screening committee. Enrolled patients were treated with the PASCAL system. Safety, effectiveness, and functional and quality-of-life outcomes were assessed. Study oversight also included an echocardiographic core laboratory and clinical events committee. Results: The study enrolled 98 patients (37.2% ≥2 independent significant jets, 15.0% severe bileaflet/multi scallop prolapse, 13.3% mitral valve orifice area <4.0 cm2, and 10.6% large flail gap and/or large flail width). The implant success rate was 92.9%. The 30-day composite major adverse event rate was 11.2%. At 6 months, 92.4% patients achieved MR ≤2+ and 56.1% achieved MR ≤1+ (P < 0.001 vs baseline). The Kaplan-Meier estimates for survival, freedom from major adverse events, and heart failure hospitalization at 6 months were 93.7%, 85.6%, and 92.6%, respectively. Patients experienced significant symptomatic improvement compared with baseline (P < 0.001). Conclusions: The outcomes of the PASCAL IID registry establish the PASCAL system as a useful therapy for prohibitive surgical risk DMR patients with complex mitral valve anatomy.
AB - Background: Mitral valve transcatheter edge-to-edge repair is safe and effective in treating degenerative mitral regurgitation (DMR) patients at prohibitive surgical risk, but outcomes in complex mitral valve anatomy patients vary. Objectives: The PASCAL IID registry assessed safety, echocardiographic, and clinical outcomes with the PASCAL system in prohibitive risk patients with significant symptomatic DMR and complex mitral valve anatomy. Methods: Patients in the prospective, multicenter, single-arm registry had 3+ or 4+ DMR, were at prohibitive surgical risk, presented with complex anatomic features based on the MitraClip instructions for use, and were deemed suitable for the PASCAL system by a central screening committee. Enrolled patients were treated with the PASCAL system. Safety, effectiveness, and functional and quality-of-life outcomes were assessed. Study oversight also included an echocardiographic core laboratory and clinical events committee. Results: The study enrolled 98 patients (37.2% ≥2 independent significant jets, 15.0% severe bileaflet/multi scallop prolapse, 13.3% mitral valve orifice area <4.0 cm2, and 10.6% large flail gap and/or large flail width). The implant success rate was 92.9%. The 30-day composite major adverse event rate was 11.2%. At 6 months, 92.4% patients achieved MR ≤2+ and 56.1% achieved MR ≤1+ (P < 0.001 vs baseline). The Kaplan-Meier estimates for survival, freedom from major adverse events, and heart failure hospitalization at 6 months were 93.7%, 85.6%, and 92.6%, respectively. Patients experienced significant symptomatic improvement compared with baseline (P < 0.001). Conclusions: The outcomes of the PASCAL IID registry establish the PASCAL system as a useful therapy for prohibitive surgical risk DMR patients with complex mitral valve anatomy.
KW - CLASP IID
KW - PASCAL system
KW - challenging mitral valve anatomy
KW - mitral valve transcatheter edge-to-edge repair (M-TEER)
KW - small mitral valve
KW - transcatheter mitral valve repair (TMVr)
UR - http://www.scopus.com/inward/record.url?scp=85146625327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146625327&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2022.11.034
DO - 10.1016/j.jacc.2022.11.034
M3 - Article
C2 - 36725171
AN - SCOPUS:85146625327
SN - 0735-1097
VL - 81
SP - 431
EP - 442
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 5
ER -